- BriaCell Therapeutics (BCTX, Financial) reports complete resolution of brain metastasis in a breast cancer patient after 18+ months of treatment.
- The patient, previously unresponsive to 8 treatment regimens, shows continued orbital tumor reduction over 21 months.
- 29 treatment cycles of Bria-IMT™ immunotherapy indicate potential efficacy for patients with limited options.
BriaCell Therapeutics (BCTX), a clinical-stage biotechnology company, has announced promising results from its ongoing Phase 2 study of the Bria-IMT™ immunotherapy in patients with advanced metastatic breast cancer. A patient who had previously failed to respond to eight different treatment regimens has shown a complete resolution of a temporal lobe brain metastasis after more than 18 months of therapy.
This patient, suffering from severe "eye-bulging" due to orbital metastasis, has experienced sustained tumor regression, with serial imaging at 8, 11, and 20 months confirming no detectable disease in the brain and continued reduction of the orbital lesion. The patient's tumor markers have remained significantly reduced from the baseline, further supporting the sustained radiologic response.
The patient has completed 29 treatment cycles over a period of 21 months, demonstrating both the potential efficacy and manageable safety profile of the Bria-IMT™ immunotherapy combined with a checkpoint inhibitor. This case highlights the potential for Bria-IMT to offer a durable therapeutic option for late-stage breast cancer patients with brain metastases who have limited treatment options and poor prognosis.
Dr. William V. Williams, President & CEO of BriaCell, expressed optimism about these findings, stating that the long-term response observed reinforces the potential of Bria-IMT to improve outcomes for patients while maintaining a favorable tolerability profile. As the trial progresses, BriaCell continues to monitor the effectiveness of this novel treatment in transforming cancer care.
